Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) CFO Sells 18,959 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMSGet Free Report) CFO Oluyemi Okupe sold 18,959 shares of Hims & Hers Health stock in a transaction on Friday, December 20th. The shares were sold at an average price of $25.77, for a total value of $488,573.43. Following the completion of the transaction, the chief financial officer now owns 132,578 shares of the company’s stock, valued at approximately $3,416,535.06. This trade represents a 12.51 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Oluyemi Okupe also recently made the following trade(s):

  • On Monday, November 25th, Oluyemi Okupe sold 101,993 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.62, for a total value of $3,021,032.66.
  • On Wednesday, November 13th, Oluyemi Okupe sold 142,886 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.93, for a total transaction of $4,276,577.98.
  • On Monday, October 14th, Oluyemi Okupe sold 269,739 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.31, for a total transaction of $5,478,399.09.
  • On Monday, October 7th, Oluyemi Okupe sold 9,868 shares of Hims & Hers Health stock. The stock was sold at an average price of $19.96, for a total value of $196,965.28.

Hims & Hers Health Stock Up 5.3 %

Shares of HIMS stock traded up $1.40 during mid-day trading on Monday, reaching $27.60. 10,968,314 shares of the company’s stock traded hands, compared to its average volume of 10,082,213. The company’s 50-day moving average price is $25.78 and its 200-day moving average price is $21.26. The company has a market cap of $6.03 billion, a P/E ratio of 62.73 and a beta of 1.25. Hims & Hers Health, Inc. has a 12 month low of $8.09 and a 12 month high of $35.02.

Hims & Hers Health (NYSE:HIMSGet Free Report) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. During the same quarter in the prior year, the company earned ($0.04) earnings per share. The business’s revenue was up 77.1% compared to the same quarter last year. Equities analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on HIMS shares. Piper Sandler restated a “neutral” rating and set a $21.00 price objective (up previously from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. Canaccord Genuity Group increased their price objective on Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research report on Monday, December 2nd. Deutsche Bank Aktiengesellschaft boosted their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. TD Cowen reiterated a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Finally, Morgan Stanley initiated coverage on shares of Hims & Hers Health in a report on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price objective for the company. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $22.80.

Read Our Latest Stock Analysis on HIMS

Institutional Investors Weigh In On Hims & Hers Health

A number of institutional investors have recently modified their holdings of the stock. Quest Partners LLC boosted its stake in Hims & Hers Health by 22.6% in the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after purchasing an additional 807 shares in the last quarter. CWM LLC raised its holdings in Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after buying an additional 1,054 shares during the last quarter. Arizona State Retirement System lifted its stake in shares of Hims & Hers Health by 3.0% in the second quarter. Arizona State Retirement System now owns 40,344 shares of the company’s stock worth $815,000 after buying an additional 1,173 shares in the last quarter. Victory Capital Management Inc. grew its holdings in shares of Hims & Hers Health by 6.6% during the second quarter. Victory Capital Management Inc. now owns 19,469 shares of the company’s stock valued at $393,000 after buying an additional 1,212 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its holdings in Hims & Hers Health by 679.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after acquiring an additional 1,603 shares during the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

About Hims & Hers Health

(Get Free Report)

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.

Featured Stories

Insider Buying and Selling by Quarter for Hims & Hers Health (NYSE:HIMS)

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.